Company profile
Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology: Pharmaceutical Preparations
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05232916 | phase3 | recruiting | 2022-12-16 | 2031-12-01 | Greenwich LifeSciences, Inc. | Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects |
FDA applications (0)
No records yet.